A Novel PRKAR1A::MET Fusion Dramatic Response to Crizotinib in a Patient with Unresectable Lung Cancer

Clin Lung Cancer. 2023 Jan;24(1):e50-e54. doi: 10.1016/j.cllc.2022.10.001. Epub 2022 Oct 14.
No abstract available

Keywords: First-line treatment; MET fusion; MET inhibitor; Next-generation sequencing; Non-small cell lung cancer.

Publication types

  • Case Reports

MeSH terms

  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • Carcinoma, Non-Small-Cell Lung* / genetics
  • Crizotinib / therapeutic use
  • Cyclic AMP-Dependent Protein Kinase RIalpha Subunit
  • Humans
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / genetics
  • Oncogene Proteins, Fusion / genetics
  • Protein Kinase Inhibitors / therapeutic use
  • Transcription Factors

Substances

  • Crizotinib
  • Protein Kinase Inhibitors
  • Transcription Factors
  • Oncogene Proteins, Fusion
  • PRKAR1A protein, human
  • Cyclic AMP-Dependent Protein Kinase RIalpha Subunit